STAT6-targeting antisense oligonucleotides against solitary fibrous tumor
Authors:
Open Access
- 15 February 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 35 (2) , 102154
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation
This publication has 66 references indexed in Scilit:
- JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XLMolecular Oncology, 2023
- ISG15 as a prognostic biomarker in solitary fibrous tumourCellular and Molecular Life Sciences, 2022
- Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case reportCurrent Problems in Cancer: Case Reports, 2022
- Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigmEBioMedicine, 2021
- Nucleic acid delivery for therapeutic applicationsAdvanced Drug Delivery Reviews, 2021
- p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell CarcinomasCell Reports, 2019
- The NAB2–STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencingCancer Genetics, 2016
- Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Investigational New Drugs, 2013
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer, 2011
- Management of recurrent meningeal hemangiopericytomaCancer, 1998